BioCryst Pharmaceuticals (BCRX) Stock Forecast & Price Target

BioCryst Pharmaceuticals Inc. demonstrates a positive outlook driven by the anticipated long-term revenue stability from Orladeyo, particularly as its pediatric use expands, allowing for sustained patient adherence throughout critical growth years. The company reported strong sales for Orladeyo in the third quarter of 2025, achieving $159.1 million—up 37% year-over-year—and indicating growing acceptance among prescribers and patients in a maturing market. Additionally, the strategic acquisition of navenibart positions BioCryst to enhance its presence in the prophylactic hereditary angioedema treatment space, suggesting further growth potential both in the near term and over the longer horizon.

BioCryst Pharmaceuticals Inc. is facing a challenging outlook due to anticipated stagnation or decline in the usage of its primary drug, Orladeyo, with forecasts suggesting a potential market share reduction to 13% over the next two years. Survey data indicates a concerning trend among current prescribers, with an expected 17% decrease in Orladeyo usage, reflecting inherent vulnerabilities within its prescriber base. Additionally, the rising market penetration of longer-acting injectable therapies is expected to significantly impact Orladeyo sales, contributing to a decline projected to reach $524 million by 2035, exacerbating the company's financial challenges.